At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 24 enrolled
Drug / intervention
Etanercept +1 moredrug
Likely dose
Etanercept 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicentre, Double-Blind, Placebo-Controlled, Randomized Study of Etanercept in the Treatment of Adults Patients With Refractory Heel Enthesitis in Spondylarthropathy
Wyeth is now a wholly owned subsidiary of Pfizer·interventional·Posted Jan 11, 2007·Updated Jul 20, 2010
In Brief
A Phase 4 clinical trial evaluating Etanercept and Placebo for Spondylarthropathies, Enthesitis. Completed, enrolled 24 participants across 15 sites in 3 countries.
Detailed Summary
To assess the efficacy and safety of Etanercept in patients with spondylarthropathy and refractory heel enthesitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpondylarthropathies, Enthesitis
CountriesFrance, Germany, Netherlands
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2007
First PostedJan 2007
Primary CompletionSep 2008
TodayJul 2026
First PostedJan 11, 2007
Enrollment StartJan 1, 2007
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 19.5 years ago
Interventions
Etanerceptdrug
50 mg injection once weekly
Placeboother
placebo